Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3899298 A
Publication typeGrant
Publication dateAug 12, 1975
Filing dateApr 11, 1972
Priority dateApr 11, 1972
Publication numberUS 3899298 A, US 3899298A, US-A-3899298, US3899298 A, US3899298A
InventorsRaymond A Szczesniak
Original AssigneeSquibb & Sons Inc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method and apparatus for angiotensin i determination
US 3899298 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent [1 1 Szczesniak METHOD AND APPARATUS FOR ANGIOTENSIN I DETERMINATION [75] Inventor: Raymond A. Szczesniak, Kendall Park, NJ.

[73] Assignee: E. R. Squibb & Sons, Inc.,

Princeton, NJ.

[22] Filed: Apr. 11, 1972 [21] Appl. No.: 242,956

[52] US. Cl. 23/253 R; 23/230 B; 23/253 TP; 195/1035; 424/1; 424/12; 206/223 [51] Int. Cl. GOln 33/16 [58] Field of Search 23/230 B, 253 TP, 253 R; 424/1, 12; 206/47 A, 223; 195/1035 R, 127

[ Aug. 12, 1975 Primary ExaminerR. E. Serwin Attorney, Agent, or Firm-Lawrence S. Levinson; Merle J. Smith; Burton Rodney [5 7 ABSTRACT Apparatus for determination of Angiotensin I comprises a vial of 1 Angiotensin I containing anion exchange resin, a vial of Angiotensin I standard, at least one vial of Angiotensin I Antiserum, and the following reagents: tris(hydroxymethyl)aminomethane, powdered charcoal, barbital buffer mixture, 8- hydroxyquinoline sulfate, bovine serum albumin powder, and Dimercaprol solution. The method involves the radioimmunoassay of Angiotensin I generated by the action of renin in incubated plasma samples. Antibody to Angiotensin I is employed as the specific antibody, and I Angiotensin is employed as the labeled antigen, and synthetic Angiotensin l is employed as a reference standard. Powdered charcoal is used to separate free Angiotensin I from antibody-bound Angiotensin I.

3 Claims, 1 Drawing Figure METHOD AND APPARATUS FORANGIOTENSIN I DETERMINATION BACKGROUND OF THE INVENTION Renin is an enzyme that is synthesized. stored. and released from granules contained in the juxtaglomcrular apparatus of the kidney. It is generally accepted that the major physiological role of renin is to act as the primary stimulus for maintenance of body sodium balance. Plasma renin activity is increased when there is a decreased renal perfusion pressure, and when there is a decreased delivery of sodium and water to the distal tubule. Renin acts on substrate, angiotensinogen. an a-2globulin produced by the liver, to form a decapeptide, Angiotensin I. Angiotensin l is biologically inactive, and is converted to the biologically active octapeptide, Angiotensin II, in the pulmonary circulation. Angiotensin II acts as a highly potent vasopressor, and stimulates the adrenal gland to produce aldosterone. Aldosterone promotes the reabsorption of sodium by the distal tubule. and when secreted in excessive amounts, results in hypertension.

Plasma renin assays have been found to be a useful adjunct in determining whether hypertension is due to primary aldosteronism or to renal vascular disease. The hypertensive patient that has plasma renin levels suppressed below normal, and has a high aldosterone secretion rate will usually be found to have adrenal hyperplasia or an adenoma of the zona glomerulosa of the adrenal gland. In patients with renal artery stenosis. the renal venous blood from the ischemic kidney may be found to have higher plasma renin levels than renal venous blood from the unaffected kidney.

OBJECTS OF THE INVENTION It is an object of the present invention to provide a kit and a method for the determination of Angiotensin I. Another object is to provide means for determining whether hypertension is due to primary aldosteronism or to renal vascular disease. A further object is to provide a kit and a method for the radioimmunoassay of Angiotensin I. These and other objects of the present invention will be apparent from the following description.

BRIEF DESCRIPTION OF THE DRAWINGS The drawing is a perspective view of the kit according to the present invention with the top removed for viewing of the contents.

DETAILED DESCRIPTION Measurement of body constituents by the technique of radioimmunoassay offers a bioanalytical tool that combines the extreme sensitivity of radioisotope methodology with the extreme specificity of immunological techniques. The procedure requires a specific antibody, a radiolabeled antigen. a pure sample of the antigen to serve as a reference standard, and a means of separation of free antigen from antibody bound antigen. The procedure follows the basic principle of saturation analysis, where there is competition between labeled and unlabeled antigen for a fixed number of antibody binding sites. As the concentration of unlabeled synthetic antigen (the substance actually being measured) increases, less of the added radiolabeled antigen will be bound to the antibody. When equilibrium has been reached in the antigen-antibody reaction, the free and bound components of the mixture are separated, and the relative amounts of each are determined by measuring the radioactivity of the separated components. The absolute quantity of unlabeled antigen in the sample being analyzed is determined by comparing the assay results to a standard curve prepared with known amounts of the unlabeled antigen.

Since purified renin is not available, the direct radio immunoassay of renin is not yet possible. In lieu ofa direct renin radioimmunoassay, a mcthos has been devel oped for the estimation of plasma renin activity through the radioimmunoassay, of Angiotensin I generated by the action of renin in incubated plasma samples. The radioimmunoassay for Angiotensin I and its application to the determination of plasma renin activity is of great value in studying physiological processes associated with hypertension and important in the clinical evaluation of hypertensive disease. The measurement of plasma renin activity by radioimmunoassay has several advantages over the standard bioassay procedures. The simplicity, specificity, and rapidity with which the radioimmunoassay can be performed remove the obstacles to routine clinical determination of plasma renin activity that were associated with the more complex bioassay procedure.

The use of "*I rather than I considerably lengthens the shelf-life of the radioiodinated Angiotensin l employed in the test. and reduces radiation exposure to laboratory personnel. The half-life of I is 60 days.

The apparatus for testing for Angiotensin I according to the present invention comprises a chassis having a plurality of receptacles for receiving vessels containing Angiotensin I antiserum, Angiotensin 1 standard, and 1 Angiotensin I. Preferably the chassis contains a plu rality of vessels containing Angiotensin I antiserum,

Angiotensin I is a decapeptide having the following amino acid sequence:

L-Asp-L-Arg-L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phc- L-HisL-Leu.

This decapeptide is prepared synthetically and is commercially available. The Angiotensin I standard is an acetic acid solution containing about 10 picograms of Angiotensin l per microliter. The acetic acid may have a concentration of from about 0.000l mole to about l.O mole. The I Angiotension I consists of an aqueous solution of I labeled Angiotensin I having a total activity of about 20 ,LCi. Preferably. this solution contains some acetic acid. A strip of paper about 2.54 cm in area impregnated with anion exchange resin (WE-2 resin paper) is also present in the vial containing the 1 labeled Angiotensin I to scavenge iodide ion released from the 1 Antiotensin l and thus maintain a low level of free iodide ion.

The Angiotensin I antiserum is obtained from the blood serum of rabbits which have been injected with Angiotensin I poly-L-lysine conjugate.

In carrying out the radioimmunoassay of the present invention, a number of test reagents are required. These reagents are as follows:

1. Tris acetate buffer [tris(hydroxymethyl )aminomethane], 7.26 g.

2. Charcoal, powdered, 3.75 g.

3. Barbital buffer mixture: sodium barbital, 0.883 g; sodium chloride, 4.59 g; sodium acetate trihydrate, 0.582 g.

4. 8-Hydroxyquinoline, 660 mg.

5. Dimercaprol solution, 2 ml. (contains 200 mg. di-

mercaprol and 400 mg. benzyl benzoate in peanut oil) 6. Bovine serum albumin fraction V powder. g.

While bovine serum albumin is preferred. any other albumin may be used. Examples of other albumins are egg albumin, mycogen of muscle, lactalbumin of milk. legumelin of peas and leucosin of wheat. in lieu of albumin, a protein having a molecular weight of from about 75,000 to about 4,000,000 may be used.

As shown in the drawing, the kit consists of a bottom member 10 formed of shockresistant material. e.g., polystyrene foam, having a plurality of receptacles 12-18 and a top closure 11. Receptacle 12 contains a vial 19 of 1 Angiotensin l, receptacle 13 contains a vial 20 of Angiotensin 1 standard, and receptacles 14-18 each contain, respectively. vials 2125 of Angiotensin l antiserum.

ln carrying out the test procedure according to the present invention, it is necessary to first prepare the test reagent.

PREPARATlON OF TEST REAGENTS l. Tris Acetate Buffer: Transfer the entire contents (7.26 g) of the vial containing Tris(hydroxymethyl- )aminomethane (TRIS) to a suitable container and add 600 ml of distilled water. Adjust the solution to pH 9.0 $0.5 using a few drops -0.4 ml) of glacial acetic acid. Store final solution at 28C.

2. Tris Acetate Buffer with BSA: For each milliliter of final solution desired, add 25 milligrams of the bovine serum albumin powder that is supplied with the kit. This solution can be stored up to one month when kept at 28C.

3. Charcoal Suspension: Transfer the entire contents of the vial labeled Barbital Buffer Mixture (6.055 g) to a suitable container and add 600 ml of distilled water. Adjust the solution to pH 9.0 i 0.5 by adding 0.2 N HCl (-l ml). The 0.2 N HCl can be prepared by diluting 2 ml of concentrated HCl to I25 ml with distilled water.

To prepare the charcoal suspension, add the entire contents (3.75 g) of the vial containing powdered charcoal to the above solution and stir vigorously for several minutes. Store the suspension at 28C. and stir vigorously before removing aliquots for use. 4. 8- Hydroxyquinoline Solution: Transfer the entire contents (660 mg) of the vial containing 8- hydroxyquinoline sulfate to a suitable container and bring to a volume of 10 ml with distilled water. Store in the dark. 5. Dimercaprol Solution: No further processing of this reagent is required before use. Shake well before use. 6. Diluted 1 Angiotensin l: Dilute a portion of the l Angiotensin I supplied with the kit with the Tris Acetate Buffer with BSA (prepared in Step 2 above) so that the final solution has a radioactivity concentration of approximately 5000 counts per minute per milliliter. Approximately 02 ml of the radioactive solution diluted to 100 ml will give the desired 5000 cpm/ml. The required volume will vary with the efficiency and discriminator settings on the counting equipment used. The diluted 1 Angiotensin I should be stored at 28C. and prepared fresh each week.

COLLECTION OF BLOOD SAMPLES FOR ANALYSIS Blood should be collected in a cold tube containing EDTA. The blood samples should be stored under refrigeration. and centrifuged in the cold to collect the plasma. Plasma samples should be frozen until usedv INCUBATION OF PLASMA SAMPLES TO GENERATE ANGIOTENSIN I To 1.0 ml of plasma, collected in the manner described above, add 10 microliters (pl) of 8- Hydroxyquinoline Solution and l0 ,ul. of Dimercaprol Solution. Transfer 0.5 ml of the above mixture to another test tube and incubate at 4C. for 3 hours. lncubate the original test tube at 37C. for 3 hours. The sample incubated at 4C. will reflect circulating levels of Angiotensin I, while the sample incubated at 37C. will reflect the quantity of Angiotensin 1 generated through the action of renin in the plasma sample. The net quantity of Angiotensin 1 generated at 37C. is calculated by subtracting the Angiotensin I level in the sample. If the incubated samples are not used immediately in the radioimmunoassay procedure described below, the samples should be frozen until used.

RADIOIMMUNOASSAY TEST PROCEDURE The procedure described below is based on performance of duplicate analyses on all samples assayed. It is recommended that all assays be conducted in plastic test tubes.

1. Mark a series of plastic test tubes with the numbers l through 16. The first 12 tubes are required for preparation of the standard curve, and the remaining four tubes are required for one clinical sample. Four additional tubes should be used for each additional clinical sample to be assayed.

2. Add 1.0 ml of diluted 1 Angiotensin l to each tube.

3. Add the following quantities of Angiotensin 1 (Al) Standard to the respective tubes: Tubes 3 and 4-5 ,ul.; tubes 5 and 6l0 ,u.l.: tubes 7 and 820 pl; tubes 9 and l0-30 pl; tubes 11 and l250 #l.

4. Add 50 pl. of the clinical sample incubated at 4C. to tubes l3 and 14.

5. Add 50 ,u.l. of the clinical sample incubated at 37C. to tubes 15 and 16.

The composition of the l6 tubes is summarized below:

6. Add 50 ul. of Angiotensin l Antiserum to all tubes, mix gently, and incubate in refrigerator (4C.) for 24 i 2 hours.

7. At the end of the incubation period add 1.0 ml of the charcoal suspension to all tubes. Mix gently and then centrifuge for 23' minutes at 30004000 rpm.

8. Decant the supernatant from each tube into simi- PRA (ng/ml/hr) larly numbered tubes.

9. Measure the radioactivity in all tubes (i.e.. tubes containing charcoal residue and tubes containing supernatant) by counting in a standard well-type gamma scintillation counter (discriminator settings 50 Kev). Subtract background cpm and record net cpm for each tube.

10. Calculate the 7: Bound (AI bound to antibody) per hour of incubation at 37C. as follows:

(lbO-IO) X 20 PRA= 3 X 1000 1.0 ng/ml/hr.

While the foregoing specification has indicated that for each of the original tubes using the following for- 15 the anion exchange resin is in the vial containing the mula, and record results.

% Bmmd Activitv in Supernatant tube (cpm) IOU For example:

Tube No. l Supernatant2400 cpm Tube No. l Charcoal -2600 cpm 7: Bound (Tube No. I J W48?! 1 l Calculate the average 72 Bound values for the duplicate samples and record average values.

l2. Prepare a Standard Curve by plotting the average "/1 Bound values against the quantity of Angiotensin I Standard added to the respective tubes (i.e.. tubes 1 through l2).

l3. Determine the quantity (,uug) of Angiotensin I in the 4C. sample and the 37C. sample by referring to the standard curve prepared above. The 7( Bound for each sample will correspond to the specific quantity of Angiotensin I contained in the sample.

14. Calculate plasma renin activity (PRA) in terms of nanograms of Angiotensin I generated per ml of plasma "I labeled Angiotensin I, it is to be understood that the Activity in Supernatant tube (cpm) Activity in charcoal tube (cpm) anion exchange resin need not be present in this vial but be present in a separate container in the kit. in which case the person performing the test may add it to the vial containing the Angiotensin I.

What is claimed is:

1. Apparatus for determination of Angiotensin I comprising a carrier being compartmented to receive at least three vials and to maintain said vials in close confinement. a first vial comprising an acetic acid solution containing about IO picograms of Angiotensin I per microliter. a second vial of Angiotensin I antiserum, and a third vial comprising an aqueous solution of l Angiotensin I having a total activity of about 20 microcuries, and having therein a strip of paper. said paper impregnated with an anion exchange resin.

2. Apparatus in accordance with claim 1 which contains a plurality of vials of Angiotensin I antiserum.

3. Apparatus in accordance with claim 2 which con tains 5 vials of Angiotensin l antiserum.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3516794 *Dec 14, 1964Jun 23, 1970Squibb & Sons IncApparatus and method for determining thyroid function
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3984532 *Sep 9, 1975Oct 5, 1976Fernandez De Castro Aurora LMethod for quantitative determination of renin activity in blood employing phenyl methyl sulfonyl fluoride and polyethylene glycol
US4041147 *Jul 29, 1976Aug 9, 1977E. R. Squibb & Sons, Inc.Angiotensin iradioimmunoassay
US4094963 *May 20, 1976Jun 13, 1978Cornell Research Foundation, Inc.Means for testing for pregnancy
US4112064 *Feb 22, 1977Sep 5, 1978Hoffmann-La Roche Inc.Stabilized angiotensin I solutions
US4130395 *Aug 19, 1975Dec 19, 1978Beth Israel Medical CenterProcess and apparatus for detection of specific biological factors by means of osmotic hemolysis
US4141965 *Sep 7, 1977Feb 27, 1979National Research Development CorporationAssay of immune complexes
US4160645 *Jul 14, 1977Jul 10, 1979Syva CompanyCatalyst mediated competitive protein binding assay
US4195059 *Jun 3, 1977Mar 25, 1980Aquaphase Laboratories, Inc.Chemical test kit
US4199559 *Feb 7, 1977Apr 22, 1980Syva CompanyFluorescence quenching with immunological pairs in immunoassays
US4200613 *Apr 14, 1978Apr 29, 1980Ramco Laboratories Inc.Radioimmunoassay apparatus
US4205952 *May 10, 1977Jun 3, 1980Technion Research & Development Foundation Ltd.Specific binding assay method and reagent means
US4210622 *Jul 21, 1978Jul 1, 1980National Research Development CorporationKit for assay of immune complexes
US4230664 *Jan 23, 1979Oct 28, 1980Technion Research & Development Foundation Ltd.Test pack kit for immunoassay
US4273867 *Apr 5, 1979Jun 16, 1981Mallinckrodt, Inc.Method and reagent for counteracting lipemic interference
US4273869 *Apr 16, 1979Jun 16, 1981The Regents Of The University Of MinnesotaCystic fibrosis detection method
US4282002 *Sep 6, 1979Aug 4, 1981Akzona IncorporatedSensitized sheep stroma immunoassay for rheumatoid factor
US4409200 *Apr 28, 1980Oct 11, 1983Research CorporationReverse transcriptase from human milk, method for its purification, and its use in the detection of breast cancer
US4600690 *Jul 19, 1983Jul 15, 1986Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva UniversityImmunoassay
US4617278 *Oct 1, 1985Oct 14, 1986Bert KeenanPetroleum alcohol test kit and method of testing petroleum for alcohol content
US4668624 *Feb 28, 1979May 26, 1987E.I. Du Pont De Nemours And CompanyProtein translation method
US7235063 *Aug 20, 2002Jun 26, 2007D'antonio Consultants International, Inc.Hypodermic injection system
US8348907Jan 8, 2013D'antonio Consultants International Inc.Hypodermic injection system
US20030040715 *Aug 20, 2002Feb 27, 2003D'antonio Nicholas F.Hypodermic jet injection kit
US20080015512 *Jun 25, 2007Jan 17, 2008D' Antonio Consultants International, Inc.Hypodermic injection system
CN102749456A *Jun 26, 2012Oct 24, 2012博奥赛斯(天津)生物科技有限公司Kit for chemilumineseent quantitative immunoassay of angiotensin I and preparation method thereof
CN102749456B *Jun 26, 2012Nov 26, 2014博奥赛斯(天津)生物科技有限公司Kit for chemilumineseent quantitative immunoassay of angiotensin I and preparation method thereof
EP0016165A1 *Mar 11, 1980Oct 1, 1980Beckman Instruments, Inc.Method of conducting radioassay using a combined reaction/filter vial
EP0040020A2 *Apr 28, 1981Nov 18, 1981Research CorporationHuman reverse transcriptase enzyme, method for its purification, and its use in the detection of breast cancer
WO1980002294A1 *Apr 10, 1980Oct 30, 1980Univ MinnesotaCystic fibrosis detection method
U.S. Classification422/430, 930/40, 435/7.1, 206/568, 436/538, 436/808, 435/23, 206/569, 436/804, 435/810
International ClassificationG01N33/539
Cooperative ClassificationG01N33/539, Y10S435/81, Y10S436/804, Y10S436/808
European ClassificationG01N33/539